Kepler Cheuvreux Suisse SA Makes New $5 Million Investment in Amgen Inc. $AMGN

Key Points

• Kepler Cheuvreux Suisse SA initiated a new stake in Amgen, buying 17,730 shares valued at about $5.0 million in the third quarter; institutional investors now own roughly 76.5% of the stock.
• Amgen reported a quarterly earnings beat (EPS $5.29 vs. $4.76 consensus) with revenue above estimates and set FY2026 guidance of 21.60–23.00 EPS, while announcing a quarterly dividend of $2.52 (2.7% yield).
• Analysts have largely raised price targets recently (e.g., Piper Sandler to $432, Argus to $400) but the MarketBeat consensus remains a Hold with a $354 target amid mixed ratings across the street.

Kepler Cheuvreux Suisse SA acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 17,730 shares of the medical research company's stock, valued at approximately $5,003,000.

Other hedge funds also recently made changes to their positions in the company. Evelyn Partners Investment Management LLP purchased a new position in shares of Amgen in the 2nd quarter worth about $32,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the second quarter worth about $32,000. Cloud Capital Management LLC purchased a new stake in Amgen during the third quarter worth about $34,000. AXS Investments LLC bought a new stake in Amgen in the third quarter worth about $42,000. Finally, Winnow Wealth LLC bought a new stake in Amgen in the third quarter worth about $47,000. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Argus increased their target price on shares of Amgen from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Friday, February 6th. BMO Capital Markets lifted their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an "outperform" rating in a report on Wednesday, December 3rd. Piper Sandler upped their price objective on Amgen from $381.00 to $432.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Citigroup increased their price objective on Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Finally, Guggenheim raised their target price on Amgen from $305.00 to $347.00 and gave the stock a "neutral" rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $354.00.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $375.43 on Wednesday. The firm has a market capitalization of $202.38 billion, a PE ratio of 26.38, a P/E/G ratio of 3.74 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a 50-day moving average price of $355.15 and a two-hundred day moving average price of $323.95. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company's quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. Amgen's payout ratio is presently 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Pipeline and capital returns: Coverage highlights Amgen’s oncology progress and frames the company’s dividend and buyback profile as supportive of long‑term growth and income, which underpins investor confidence in cash flow stability. Amgen Oncology Advances Test Dividend Strength And Long Term Growth Story
• Positive Sentiment: Industry endorsement: CNBC commentary cites Amgen as one of the larger biotech names that could be resilient amid structural changes (e.g., limited disruption from AI), which supports defensive large‑cap biotech demand. Biotech is resistant to AI disruption. Josh Brown likes these two stocks in the industry
• Positive Sentiment: Analyst/investor idea coverage: Earnings and strategy coverage from outlets like Zacks flag Amgen as a portfolio pick under their approach, reinforcing interest from strategy-driven investors. Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
• Neutral Sentiment: Short‑interest reporting appears anomalous: Data feeds show a reported increase in short interest but list zero shares/NaN values, suggesting the spike is likely a reporting glitch rather than confirmed bearish positioning. Monitor for corrected filings. (No direct article link—data entry reported.)
• Negative Sentiment: Analyst move: Jefferies initiated coverage on AMGN with a Hold rating and a $350 price target, signaling limited upside from current levels and contributing to downward pressure on the stock. Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence
• Negative Sentiment: Policy risk: A newly introduced bill (H.R. 7871) to codify Medicaid value‑based purchasing could change how discounts/rebates and outcomes‑based payments are calculated and reported. That framework may reduce realized prices or increase rebate liabilities for manufacturers that enter VBP arrangements—a potential long‑term headwind for Amgen’s pricing and margins in Medicaid. New Bill: Representative Brett Guthrie introduces H.R. 7871: Medicaid VBPs for Patients Act

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.